Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

BACKGROUND. nab-Paclitaxel in combination with gemcitabine has emerged as a new treatment option for patients with metastatic pancreatic cancer (MPC), based on superiority over gemcitabine demonstrated in the phase III MPACT trial. Previously, Karnofsky performance status (KPS) score and the presenc...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Tabernero, Josep, Chiorean, E. Gabriela, Infante, Jeffrey R., Hingorani, Sunil R., Ganju, Vinod, Weekes, Colin, Scheithauer, Werner, Ramanathan, Ramesh K., Goldstein, David, Penenberg, Darryl N., Romano, Alfredo, Ferrara, Stefano, Von Hoff, Daniel D.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: AlphaMed Press 2015
Onderwerpen:
Gastrointestinal Cancer
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319641/
https://ncbi.nlm.nih.gov/pubmed/25582141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0394
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items